Simulations Plus Announces Quarterly Cash Dividend of $0.06 per Share and Payable on February 2

Logo
Jan. 16, 2018 20:30 UTC

 

 
 

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development, today announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.06 per share to its shareholders. The cash dividend will be distributed on Friday, February 2, to shareholders of record as of Friday, January 26, 2018.

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said, “On November 1, 2017, we announced that the board had voted to increase the quarterly cash dividend to shareholders from $0.05 to $0.06 per share as a result of our excellent financial performance during fiscal year 2017. The board has voted again to pay a $0.06 per share cash dividend, however the board always has the discretion of discontinuing, increasing, or decreasing the dividend in accordance with the cash needs of the business.”

About Simulations Plus, Inc.

Simulations Plus, Inc. is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology models for drug-induced liver injury and nonalcoholic fatty liver disease. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical, biotechnology, and chemical agents. Our software is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, chemical, and consumer goods companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at www.simulations-plus.com.

 

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche
661-723-7723
renee@simulations-plus.com
or
Hayden IR
Mr. Cameron Donahue
651-653-1854
cameron@haydenir.com

 
 

Source: Simulations Plus, Inc.

Back to news